Recombinant Human ANXA8, His-tagged

Targeting ANXA8 could potentially have therapeutic implications, especially in cancer treatment. Modulating ANXA8 expression or function might be explored as a strategy to suppress tumor growth, metastasis, or enhance chemotherapeutic responses. However, more studies are required to evaluate the feasibility and effectiveness of targeting ANXA8 for specific therapeutic interventions.

ANXA8 polymorphisms and genetic variants have been identified, but their associations with diseases are still limited and require further investigation. Some studies have reported the presence of ANXA8 polymorphisms in different populations, but their functional implications or associations with specific diseases are not well-characterized. However, as research progresses, it is possible that specific ANXA8 variants may be identified as potential genetic markers or contributors to certain diseases.

ANXA8 has been linked to certain diseases. Abnormal expression or dysregulation of ANXA8 has been observed in different types of cancer, including breast, ovarian, pancreatic, and lung cancers. It has also been implicated in autoimmune diseases, neurodegenerative disorders, and cardiovascular diseases, although further research is needed to elucidate its precise involvement in these conditions.

The potential of ANXA8 as a therapeutic target or biomarker is still under investigation. Its involvement in various cellular processes and its dysregulation in diseases suggest that it could be a target for therapeutic interventions. Additionally, its association with disease progression and prognosis in certain cancers indicates its potential as a biomarker. However, more research is needed to fully understand its clinical significance and its potential as a target for therapeutic interventions.

ANXA8 expression patterns can vary across different tissues. It is generally expressed in a wide range of tissues, including the brain, liver, lung, kidney, heart, and intestine. However, the expression levels may differ, and certain tissues may exhibit higher expression than others. For example, ANXA8 has been reported to be highly expressed in the brain, specifically in the hippocampus, cortex, and Purkinje cells of the cerebellum. In the liver, ANXA8 expression has been observed in hepatocytes. Additionally, ANXA8 expression has been detected in various cell types of the reproductive system, such as ovarian granulosa cells and Leydig cells in the testes. Overall, the expression patterns of ANXA8 suggest its involvement in multiple biological processes and cellular functions throughout the body.

Yes, ANXA8 can undergo various post-translational modifications (PTMs). These modifications can regulate its cellular localization, interactions, and functions. Some known PTMs of ANXA8 include phosphorylation, acetylation, ubiquitination, and sumoylation. Phosphorylation of ANXA8 by different kinases can modulate its binding to other proteins or cellular membranes. Acetylation can similarly affect ANXA8's activity and interactions. Ubiquitination and sumoylation can regulate ANXA8's stability and degradation. These PTMs play critical roles in fine-tuning the functions and regulation of ANXA8 in different cellular contexts.

ANXA8 is involved in various cellular and physiological processes. It has been implicated in calcium signaling and ion transport, membrane dynamics, exocytosis, endocytosis, and vesicle trafficking. ANXA8 may also play a role in cell adhesion, migration, and cytoskeletal organization.

Yes, ANXA8 has been found to interact with several proteins and molecules. Some known binding partners include membrane proteins such as S100A10, S100A11, and S100A13, which are involved in calcium signaling and cytoskeletal organization. ANXA8 has also been shown to interact with vesicle-associated proteins like clathrin, dynamin, and endophilin, suggesting a role in vesicle trafficking and membrane dynamics. Other interactors include protein kinases, phosphatases, and cytoskeletal proteins such as actin and tubulin.

Yes, ANXA8 undergoes various post-translational modifications. It can be phosphorylated, acetylated, ubiquitinated, and undergo proteolytic cleavage. These modifications can regulate its stability, localization, and interaction with other proteins, thereby influencing its cellular functions.

ANXA8 is expressed in various tissues and cell types. It has been detected in the brain, heart, liver, kidneys, lungs, gastrointestinal tract, and reproductive organs. Its expression levels may vary in different cell types and can be influenced by developmental stage, physiological conditions, and disease states.

Yes, ANXA8 has been reported to have a role in cell migration and invasion. It can promote or inhibit these processes depending on the cellular context and other interacting proteins. ANXA8 has been shown to interact with components of the actin cytoskeleton and affect cell adhesion, which are crucial for cell motility and migration.

ANXA8 has been implicated in various diseases and pathological conditions. It has been associated with cancer, where its expression levels and functions can impact tumor growth, invasion, and metastasis. ANXA8 dysregulation has also been observed in autoimmune diseases, such as systemic lupus erythematosus (SLE), and neurodegenerative disorders, including Alzheimer's disease. Its involvement in inflammation, immunity, and oxidative stress pathways suggests its potential relevance to several disease processes.

ANXA8 has shown potential as a diagnostic or prognostic marker for certain types of cancers. Altered expression levels of ANXA8 have been observed in cancer tissues compared to normal tissues, and its overexpression or downregulation has been associated with different clinical outcomes. However, more research is required to establish its reliability and clinical utility as a biomarker.

While ANXA8 knockout or transgenic animal models have not been extensively reported, there are a few studies that have utilized ANXA8 knockout or overexpression in cell culture or animal models. These studies have provided insights into the functions and roles of ANXA8 in specific cellular processes, such as cell migration, adhesion, and calcium signaling. However, further research is needed to understand the full impact of ANXA8 dysregulation in vivo.

Currently, there is limited information about genetic mutations specifically in ANXA8 that are associated with disease. However, mutations in other annexin family members have been reported in certain disorders, highlighting the potential relevance of ANXA8 mutations in disease development. Further research is needed to investigate this aspect comprehensively.

Yes, ANXA8 has been found to interact with various proteins. It can associate with other annexin family members, as well as several cytoskeletal proteins, ion channels, and membrane receptors. These interactions suggest that ANXA8 may participate in protein-protein complexes involved in cellular processes and signaling pathways.